Redx Oncology Ltd is a subsidiary of Redx Pharma, a UK-based technology development resource for the global pharmaceutical market.
The application of Redox Switch™ in oncology gives the company the opportunity to deliver multiple development candidates across a range of mechanistic approaches in cancer.
Redx Oncology is taking advantage of the local knowledge base and new biopharmaceutical laboratory infrastructure being created in central Liverpool. The company is working closely with its partners in the University of Liverpool, the Royal Liverpool University Hospital, the Liverpool Cancer Research UK Centre and Liverpool City Council (Liverpool Vision) to achieve its goal of creating new clinical candidates in support of the fight against cancer.
Monitor the research progress of Redx Oncology: Pipeline
Address: Duncan Building
Royal Liverpool University Hospital
Phone: 0151 706 4747
Fax: 0151 706 4749
Dr Derek Lindsay was previously Director of Innovation of Britest Ltd, based in Runcorn, and was formerly R&D Director of Avecia Pharmaceutical Products. Dr Lindsay is one of the founders and Chief Operating Officer of Redx Pharma. He is also Managing Director of Redx Oncology Ltd and Redx Anti-Infectives Ltd.
Dr Richard Armer has significant experience in both biotechnology and pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen and Lectus Therapeutics over the past 18 years. Richard's expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition and intellectual property. Throughout his career Richard has progressed through increasingly senior and broader roles within the organisations he has worked for and was most recently CSO at Lectus Therapeutics. Richard has been successful in identifying and progressing multiple clinical candidates across a wide range of therapeutic areas during his career to date.
Mary-Ann has 16 years experience in drug discovery in biotech and pharma companies including La Jolla Pharmaceutical, Arena, Lilly and most recently Lpath where she was Executive Director of Research. She has extensive expertise in in vitro and in vivo pharmacology in a variety of therapeutic areas including oncology and inflammation and has advanced multiple programs through discovery and into clinical development.
Dr Stuart Best has over 20 years of experience spanning both regulated bioanalytical investigations and drug discovery ADME screening for multi-national pharmaceutical companies and Contract Research Organizations. His career is distinguished by progressive applications of newer analytical technologies to characterise an expanding and ever more complex chemical space, specifically in the support ADME.
Immediately prior to Redx Oncology, Stuart was VP of Analytical Operations at Xceleron, a company specialising in the application of accelerator mass spectrometry to shorten the drug development trajectory. Stuart was with Merck in Scotland where he spent seven years with Organon then Schering-Plough.
Liverpool, L69 3GA